Nirsum has developed a series of novel small molecule candidates with potential utility in OUD and other indications. Our most advanced compounds NRS-033 and NRS-067 are internally-discovered, wholly-owned, and US patented novel compositions.  Their development is funded in part through a Cooperative Agreement with the National Institutes of Health (NIH)/ National Institute On Drug Abuse (NIDA).